Literature DB >> 476697

Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells.

M Huybrechts, M Symann, A Trouet.   

Abstract

We have compared daunorubicin (DNR)-DNA with free DNR and doxorubicin (DOX)-DNA with free DOX for their effects in vivo in mice on pluripotent stem cells and granulocytic committed stem cells. Dose-survival, time-survival, and recovery curves were obtained after one i.v. injection of either drug. The dose-survival curves of colony-forming units-spleen (CFU-S) and colony-forming units-committed stem cells (CFU-C) were exponential in shape with both agents. DNR-DNA appeared more toxic to the hemopoietic precursor cells than did free DNR. In contrast, DOX-DNA was less toxic toward CFU-S and as toxic as DOX toward CFU-C. Time-survival curves indicated a minimum level of CFU-S and CFU-C at about 33 hr. After that, the recovery of CFU-S was rapid for DNR-treated mice but remained below 50% of the controls on Day 12 for the DNR-DNA-treated group. In mice previously given injections of DOX or DOX-DNA, the recovery of the CFU-S was more protracted in time with a better recovery in mice treated with DOX-DNA. Both DNR and DNR-DNA induced an initial CFU-C decrease followed by a rapid but transient rise with a maximum on Day 4 after chemotherapy. On Day 12, the CFU-C recovery was still incomplete in both DNR- and DNR-DNA-treated mice. In the groups treated with DOX, the CFU-C recovery was more important after DOX-DNA complex than after free DOX. The results are discussed in view of the "lysosomotropic chemotherapy" hypothesis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476697

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.

Authors:  M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin.

Authors:  Y Mizuno; T Hara; S Tachibana; K Uragoh; K Akazawa; K Ueda
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  Cytotoxic effect of dose and schedule on normal murine hematopoietic progenitor cells following the administration of 4'-deoxydoxorubicin.

Authors:  I Pannacciulli; C Muzzulini; G Massa; G Bogliolo
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.